NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(1) Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of CIRCOR International, Inc. ("CIRCOR", the "Company", "us", "we" or "our") have been prepared according to the rules and regulations of the United States ("U.S.") Securities and Exchange Commission (“SEC”) for interim reporting, along with accounting principles generally accepted in the U.S ("GAAP"). In the opinion of management, the unaudited, condensed consolidated financial statements reflect all adjustments (consisting only of normal and recurring items) necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the periods presented. The Company prepares its interim financial information using the same accounting principles it uses for its annual audited consolidated financial statements. Certain information and note disclosures normally included in the annual audited consolidated financial statements have been condensed or omitted in accordance with SEC rules. The Company believes that the disclosures made in its condensed consolidated financial statements and the accompanying notes are adequate to make the information presented not misleading.
The condensed consolidated balance sheet as of December 31, 2020 was derived from CIRCOR's audited consolidated financial statements as of that date but does not include all of the information and notes required for annual financial statements. The Company recommends that the financial statements included in its Quarterly Report on Form 10-Q be read in conjunction with the consolidated financial statements and notes included in its Annual Report on Form 10-K for the year ended December 31, 2020.
CIRCOR operates and reports financial information using a fiscal year ending December 31. The data periods contained within its Quarterly Reports on Form 10-Q reflect the results of operations for the 13-week, 26-week and 39-week periods which generally end on the Sunday nearest to the calendar quarter-end date. Operating results for the three months ended April 4, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or any future quarter.
Unless otherwise indicated, all financial information and statistical data included in these notes to the Company's condensed consolidated financial statements relate to its continuing operations, with dollar amounts expressed in thousands (except share and per-share data).
COVID-19
In March 2020, the World Health Organization declared the outbreak of COVID-19, which continues to spread throughout the U.S. and the world, as a pandemic. The pandemic is having an impact on the global economy, resulting in rapidly changing market and economic conditions. As of March 29, 2020, the Company experienced a significant decline in its market capitalization below its consolidated book value. As a result, management concluded that there was a goodwill and an intangible asset impairment triggering event for the Company in the first quarter of 2020. Through its impairment analysis, the Company determined that goodwill in its Industrial segment was impaired and recognized a $116.2 million impairment charge. See Note 7, Goodwill and Intangibles, net, for additional information on the goodwill impairment.
The effects of the COVID-19 pandemic continue to negatively impact the Company's results of operations, cash flows and financial position. The Company’s condensed consolidated financial statements presented herein reflect management's estimates and assumptions regarding the effects of COVID-19 as of the date of the condensed consolidated financial statements.
(2) Summary of Significant Accounting Policies
The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended April 4, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, except as updated below with respect to newly adopted accounting standards.
The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying disclosures. Some of the more significant estimates, which are impacted by management's estimates and assumptions regarding the effects of COVID-19, relate to recoverability of goodwill and indefinite-lived trade names, estimated total costs for ongoing long-term revenue contracts where transfer of control occurs over time, inventory valuation, share-based compensation, amortization and
impairment of long-lived assets, income taxes (including valuation allowance), fair value of disposal group, pension benefits obligations, acquisition accounting, penalty accruals for late shipments, asset valuations, and product warranties. While management believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ materially from those estimates.
New Accounting Standards - Adopted
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. In January 2021, the FASB issued ASU 2021-01 which clarified the scope of Topic 848. Topic 848 contains optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships, and other areas or transactions that are impacted by reference rate reform (i.e., by the transition of LIBOR and other interbank offered rates to alternative reference interest rates). The new standard was effective upon issuance and generally can be applied to contract modifications through December 31, 2022. The Company adopted this standard as of January 1, 2021, and intends to apply the provisions of this standard to contract modifications if and when applicable. During the three months ended April 4, 2021, the adoption of the standard did not have a material impact on the Company's condensed consolidated financial statements.
On January 1, 2020, the Company adopted FASB ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. The Company adopted the standard using a modified retrospective approach through a cumulative-effect adjustment to retained earnings. It recognized the cumulative effect of adopting the new credit loss standard as an adjustment to the opening balance of retained earnings as of January 1, 2020. The adoption of the standard did not have a material impact on the Company's condensed consolidated financial statements.
(3) Discontinued Operations
Discontinued Operations
During 2020, the Company’s wholly-owned subsidiary, CIRCOR Energy Products LLC ("CEP"), completed the disposition of its DV business. The transaction is subject to an earn out of 50% of net profit (only if positive) from closing through December 31, 2022. As part of the transaction, CEP retained certain supplier liabilities and responsibility for closing CEP's Mexico manufacturing facility.
The following table presents the summarized components of income (loss) from discontinued operations of the DV business for the three months ended April 4, 2021 and March 29, 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
Net revenues
|
$
|
—
|
|
|
$
|
6,237
|
|
|
|
|
|
Cost of revenues
|
—
|
|
|
11,358
|
|
|
|
|
|
Gross (loss) profit
|
—
|
|
|
(5,121)
|
|
|
|
|
|
Selling, general and administrative expenses
|
—
|
|
|
3,139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special and restructuring charges (recoveries), net
|
(152)
|
|
|
(1,328)
|
|
|
|
|
|
Operating income (loss)
|
152
|
|
|
(6,932)
|
|
|
|
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
Interest (income), net
|
—
|
|
|
(7)
|
|
|
|
|
|
Other (income) expense, net
|
118
|
|
|
5,410
|
|
|
|
|
|
Total other (income) expense, net
|
118
|
|
|
5,403
|
|
|
|
|
|
Income (loss) from discontinued operations, before income taxes
|
34
|
|
|
(12,335)
|
|
|
|
|
|
Provision for (benefit from) income tax
|
273
|
|
|
(21,497)
|
|
|
|
|
|
Income (loss) from discontinued operations, net of tax
|
$
|
(239)
|
|
|
$
|
9,162
|
|
|
|
|
|
Assets Held for Sale
The Company completed the sale of its Cryogenic Valves business ("Cryo") during the quarter ended April 4, 2021. See Note 5, Special and Restructuring Charges (Recoveries), net for additional information on the Cryo business divestiture. As of December 31, 2020, the Cryo business satisfied the held for sale classification criteria and was reported as "held for sale" within the current assets section of our condensed consolidated balance sheet.
The following table presents the balance sheet information for assets held for sale as of December 31, 2020 (in thousands):
|
|
|
|
|
|
|
|
|
December 31, 2020
|
|
Cryo
|
|
|
|
|
|
|
Inventories
|
$
|
2,963
|
|
|
|
Prepaid expenses and other current assets
|
48
|
|
|
|
Property, plant, and equipment, net
|
162
|
|
|
|
Goodwill
|
1,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets held for sale
|
$
|
5,073
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) Revenue Recognition
The Company's revenue is derived from a variety of contracts. A significant portion of revenues are from contracts associated with the design, development, manufacture or modification of highly engineered, complex and severe environment products with customers who are either in or service the aerospace, defense and industrial markets. Contracts within the defense markets are primarily with U.S. military customers. These contracts typically are subject to the Federal Acquisition Regulations ("FAR"). The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Contracts may be modified to account for changes in contract specifications and requirements.
For revenue that is recognized from products and services transferred to customers over-time, the Company uses an input measure (e.g., costs incurred to date relative to total estimated costs at completion, known as the “cost-to-cost” method) to measure progress. The Company uses the cost-to-cost measure of progress because it best depicts the transfer of control to the customer which occurs as it incurs costs on its contracts. Under the cost-to-cost measure of progress, revenue is recognized proportionally as costs are incurred. Contract costs include labor, materials and subcontractors’ costs, other direct costs and an allocation of overhead, as appropriate.
As of April 4, 2021, the Company had $208.7 million of transaction price related to remaining performance obligations. The Company expects to recognize approximately 62% of its remaining performance obligations as revenue during the remainder of 2021, 25% in 2022, and the remaining 13% in 2023 and thereafter.
In order to determine revenue recognized during the period from contract liabilities at the beginning of the period, the Company first allocates revenue to the individual contract liabilities balances outstanding at the beginning of the period until the revenue exceeds that balance. If additional advances are received on those contracts in subsequent periods, it assumes all revenue recognized in the reporting period first applies to the beginning contract liabilities as opposed to a portion applying to the new advances for the period. Revenue recognized during the three months ended April 4, 2021 that was included in contract liabilities as of the beginning of the period amounted to $14.3 million.
Disaggregation of Revenue. The Company determined that disaggregating revenue into these categories meets the disclosure objective in Topic 606 which is to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following tables present our revenue disaggregated by major product line and geographical market (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aerospace & Defense Segment
|
|
|
|
|
|
|
|
|
Commercial Aerospace & Other
|
$
|
19,800
|
|
|
$
|
26,320
|
|
|
|
|
|
|
Defense
|
40,201
|
|
|
39,173
|
|
|
|
|
|
|
Total
|
60,001
|
|
|
65,493
|
|
|
|
|
|
Industrial Segment
|
|
|
|
|
|
|
|
|
Valves
|
45,763
|
|
|
54,190
|
|
|
|
|
|
|
Pumps
|
74,891
|
|
|
72,530
|
|
|
|
|
|
|
Total
|
120,654
|
|
|
126,720
|
|
|
|
|
|
Net Revenue
|
$
|
180,655
|
|
|
$
|
192,213
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aerospace & Defense Segment
|
|
|
|
|
|
|
|
|
|
|
EMEA
|
|
|
$
|
15,214
|
|
|
$
|
14,806
|
|
|
|
|
|
|
North America
|
|
|
41,645
|
|
|
45,988
|
|
|
|
|
|
|
Other
|
|
|
3,142
|
|
|
4,699
|
|
|
|
|
|
|
Total
|
|
|
60,001
|
|
|
65,493
|
|
|
|
|
|
Industrial Segment
|
|
|
|
|
|
|
|
|
|
|
EMEA
|
|
|
58,003
|
|
|
57,006
|
|
|
|
|
|
|
North America
|
|
|
31,788
|
|
|
43,922
|
|
|
|
|
|
|
Other
|
|
|
30,863
|
|
|
25,792
|
|
|
|
|
|
|
Total
|
|
|
120,654
|
|
|
126,720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenue
|
|
|
$
|
180,655
|
|
|
$
|
192,213
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contract Balances. The Company’s contract assets and contract liabilities balances as of April 4, 2021 and December 31, 2020 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April 4, 2021
|
|
December 31, 2020
|
|
Increase/(Decrease)
|
|
|
|
|
|
|
Contract assets:
|
|
|
|
|
|
Recorded within prepaid expenses and other current assets
|
$
|
68,155
|
|
|
$
|
67,352
|
|
|
$
|
803
|
|
Recorded within other non-current assets
|
13,684
|
|
|
10,824
|
|
|
2,860
|
|
|
$
|
81,839
|
|
|
$
|
78,176
|
|
|
$
|
3,663
|
|
|
|
|
|
|
|
Contract liabilities:
|
|
|
|
|
|
Recorded within accrued expenses and other current liabilities
|
$
|
19,356
|
|
|
$
|
23,585
|
|
|
$
|
(4,229)
|
|
Recorded within other non-current liabilities
|
7,998
|
|
|
9,412
|
|
|
(1,414)
|
|
|
$
|
27,354
|
|
|
$
|
32,997
|
|
|
$
|
(5,643)
|
|
|
|
|
|
|
|
Contract assets increased by $3.7 million during the three months period ended April 4, 2021, primarily due to unbilled revenue recognized during the period for over-time revenue contracts within our Defense business partially offset by net transfers from contract assets to receivables within our Refinery Valves business.
Contract liabilities decreased by $5.6 million during the three months period ended April 4, 2021, primarily due to recognition of revenue against customer advances within our Defense business in excess of advances received during the period.
Allowance for Credit Losses
The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses or doubtful accounts based upon expected losses, its historical experience, expectation of changes in risk of loss and any specific customer collection issues that it has identified. During the three months period ended April 4, 2021, there were no material changes in the allowance for credit losses including additional allowances, write-offs or recoveries. During the three months period ended March 29, 2020, the Company recognized a $5.9 million charge for allowance against a customer receivable, other than that there were no other material changes including additional allowances, write-offs or recoveries.
(5) Special and Restructuring Charges (Recoveries), net
Special and restructuring charges (recoveries), net
Special and restructuring charges (recoveries), net consist of restructuring costs (including costs to exit a product line or program) as well as certain special charges (recoveries) such as significant litigation settlements and other transactions (charges or recoveries) that are described below. All items described below are recorded in Special and restructuring charges (recoveries), net on our condensed consolidated statements of operations. Certain other special and restructuring charges (recoveries) such as inventory related items may be recorded in cost of revenues given the nature of the item.
The table below summarizes the amounts recorded within the special and restructuring charges (recoveries), net line item on the condensed consolidated statements of operations for the three months ended April 4, 2021 and March 29, 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special & restructuring charges (recoveries), net
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
Special charges (recoveries), net
|
$
|
(2,869)
|
|
|
$
|
(45,175)
|
|
|
|
|
|
Restructuring charges, net
|
2,060
|
|
|
2,883
|
|
|
|
|
|
Total special and restructuring charges (recoveries), net
|
$
|
(809)
|
|
|
$
|
(42,292)
|
|
|
|
|
|
Special charges (recoveries), net
The table below details the special charges (recoveries), net recognized for the three months ended April 4, 2021 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special charges (recoveries), net
|
|
Three Months Ended April 4, 2021
|
|
|
Aerospace & Defense
|
|
Industrial
|
|
Corporate
|
|
Total
|
Cryo divestiture
|
|
$
|
—
|
|
|
$
|
(1,947)
|
|
|
$
|
—
|
|
|
$
|
(1,947)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other special charges (recoveries), net
|
|
15
|
|
|
(629)
|
|
|
(308)
|
|
|
(922)
|
|
Total special charges (recoveries), net
|
|
$
|
15
|
|
|
$
|
(2,576)
|
|
|
$
|
(308)
|
|
|
$
|
(2,869)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryo divestiture: During the three months ended April 4, 2021, the Company recognized a net special recovery of $1.9 million from the sale of the Cryo business. The Company received cash proceeds of $7.2 million and recognized a pre-tax gain on sale of $1.9 million.
Other special charges (recoveries), net: The Company recognized special recoveries of $0.6 million for the three months ended April 4, 2021, with recoveries partially offset by charges from initiatives to streamline operations and reduce costs in the Industrial segment. The Company also recognized recoveries of $0.3 million in Corporate.
The table below details the special charges (recoveries), net recognized for the three months ended March 29, 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special charges (recoveries), net
|
|
Three Months Ended March 29, 2020
|
|
|
Aerospace & Defense
|
|
Industrial
|
|
Corporate
|
|
Total
|
I&S divestiture
|
|
$
|
—
|
|
|
$
|
(53,202)
|
|
|
$
|
—
|
|
|
$
|
(53,202)
|
|
Professional fees to review and respond to an unsolicited tender offer to acquire the Company
|
|
—
|
|
|
—
|
|
|
2,355
|
|
|
2,355
|
|
Amortization of debt issuance fee
|
|
—
|
|
|
—
|
|
|
3,541
|
|
|
3,541
|
|
Other special charges
|
|
—
|
|
|
101
|
|
|
2,030
|
|
|
2,131
|
|
Total special charges (recoveries), net
|
|
$
|
—
|
|
|
$
|
(53,101)
|
|
|
$
|
7,926
|
|
|
$
|
(45,175)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I&S Divestiture: In 2020, the Company recorded net special recoveries of $53.2 million for the three months ended March 29, 2020, attributed to the sale of the I&S business in January 2020. During the quarter ended March 29, 2020, the Company received net cash proceeds of $169.8 million and recognized a pre-tax gain on sale of $54.6 million. The Industrial segment incurred $1.4 million of operating expenses associated with the I&S business for the three months ended March 29, 2020, which are presented net within the I&S divestiture line.
Professional fees: The Company incurred special charges of $2.4 million for the three months ended March 29, 2020, associated with the review and response to an unsolicited tender offer to acquire the Company.
Amortization of debt issuance fee: The Company incurred special charges of $3.5 million for the three months ended March 29, 2020 for accelerated amortization of capitalized debt issuance costs in connection with the accounting for the paydown and refinancing of its term loan during the first quarter of 2020. See Note 9, Financing Arrangements, for additional information on our debt repricing.
Other cost savings initiatives: The Company incurred special charges of $2.1 million for the three months ended March 29, 2020, associated with professional fees for projects to streamline operations and reduce costs of $1.2 million, costs of a cyber incident of $0.7 million and charges related to previous business sales of $0.2 million.
Restructuring charges, net
The tables below detail the charges associated with restructuring actions recorded for the three months ended April 4, 2021 and March 29, 2020. Accruals associated with the restructuring actions are recorded within Accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring charges, net
|
|
|
As of and for the Three Months Ended April 4, 2021
|
|
|
Aerospace & Defense
|
|
Industrial
|
|
Corporate
|
|
Total
|
Facility related charges
|
|
$
|
8
|
|
|
$
|
(75)
|
|
|
$
|
—
|
|
|
$
|
(67)
|
|
Employee related charges
|
|
833
|
|
|
976
|
|
|
318
|
|
|
2,127
|
|
Total restructuring charges, net
|
|
$
|
841
|
|
|
$
|
901
|
|
|
$
|
318
|
|
|
$
|
2,060
|
|
|
|
|
|
|
|
|
|
|
Accrued restructuring charges as of December 31, 2020
|
|
|
|
|
|
|
|
$
|
1,512
|
|
Total charges, net (shown above)
|
|
|
|
|
|
|
|
2,060
|
|
Charges paid / settled, net
|
|
|
|
|
|
|
|
(1,777)
|
|
Accrued restructuring charges as of April 4, 2021
|
|
|
|
|
|
|
|
$
|
1,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company expects to make payment or settle the majority of the restructuring charges accrued as of April 4, 2021 during the next nine months.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring charges, net
|
|
|
As of and for the Three Months Ended March 29, 2020
|
|
|
Aerospace & Defense
|
|
Industrial
|
|
Corporate
|
|
Total
|
Facility related charges
|
|
$
|
10
|
|
|
$
|
1,632
|
|
|
$
|
—
|
|
|
$
|
1,642
|
|
Employee related charges
|
|
—
|
|
|
1,058
|
|
|
183
|
|
|
1,241
|
|
Total restructuring charges, net
|
|
$
|
10
|
|
|
$
|
2,690
|
|
|
$
|
183
|
|
|
$
|
2,883
|
|
|
|
|
|
|
|
|
|
|
Accrued restructuring charges as of December 31, 2019
|
|
|
|
|
|
|
|
$
|
5,199
|
|
Total charges, net (shown above)
|
|
|
|
|
|
|
|
2,883
|
|
Charges paid / settled, net
|
|
|
|
|
|
|
|
(4,154)
|
|
Accrued restructuring charges as of March 29, 2020
|
|
|
|
|
|
|
|
$
|
3,928
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Descriptions of the restructuring actions is provided in the section titled "Restructuring Programs Summary" that follows.
Restructuring Programs Summary
The Company recorded $2.1 million of restructuring charges during the three months ended April 4, 2021 to reduce expenses, primarily through reductions in force across both administrative functions and manufacturing operations. The Company initiated plans in Q1 2021 to restructure employees at certain sites, and recognized $1.2 million of charges in connection with these plans in the current quarter. The Company incurred additional charges of $0.9 million, to restructure operations in the current quarter, from plans initiated in 2020.
During the three months ended March 29, 2020, the Company recorded $2.9 million of restructuring charges, principally in the Industrial segment, to reduce expenses primarily through reductions in force and the consolidation of sales operations.
(6) Inventories
Inventories consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
April 4, 2021
|
|
December 31, 2020
|
Raw materials
|
$
|
63,935
|
|
|
$
|
63,255
|
|
Work in process
|
50,494
|
|
|
45,867
|
|
Finished goods
|
20,862
|
|
|
19,962
|
|
Total inventories
|
$
|
135,291
|
|
|
$
|
129,084
|
|
(7) Goodwill and Intangibles, net
The following table shows goodwill by segment as of December 31, 2020 and April 4, 2021 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aerospace & Defense
|
|
Industrial
|
|
|
Total
|
Goodwill as of December 31, 2020
|
|
$
|
57,574
|
|
|
$
|
101,370
|
|
|
|
$
|
158,944
|
|
|
|
|
|
|
|
|
|
Currency translation adjustments
|
|
(61)
|
|
|
(1,966)
|
|
|
|
(2,027)
|
|
Goodwill as of April 4, 2021
|
|
$
|
57,513
|
|
|
$
|
99,404
|
|
|
|
$
|
156,917
|
|
|
The Company performs an impairment assessment for goodwill at the reporting unit level on an annual basis as of the end of our October month end, or more frequently if circumstances warrant. At April 4, 2021, the Company performed a review and determined there were no triggering events requiring an impairment assessment.
The table below presents gross intangible assets and the related accumulated amortization as of April 4, 2021 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Carrying Value
|
Patents
|
$
|
5,368
|
|
|
$
|
(5,368)
|
|
|
$
|
—
|
|
Customer relationships
|
305,774
|
|
|
(118,096)
|
|
|
187,678
|
|
Acquired technology
|
136,974
|
|
|
(63,317)
|
|
|
73,657
|
|
|
|
|
|
|
|
Total Amortized Intangibles
|
$
|
448,116
|
|
|
$
|
(186,781)
|
|
|
$
|
261,335
|
|
|
|
|
|
|
|
Non-amortized intangibles (primarily trademarks and trade names)
|
$
|
76,529
|
|
|
$
|
—
|
|
|
$
|
76,529
|
|
Total Non-Amortized Intangibles
|
$
|
76,529
|
|
|
$
|
—
|
|
|
$
|
76,529
|
|
Net carrying value of intangible assets
|
|
|
|
|
$
|
337,864
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The table below presents estimated remaining amortization expense for intangible assets recorded as of April 4, 2021 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2022
|
|
2023
|
|
2024
|
|
2025
|
|
After 2025
|
|
|
Estimated amortization expense
|
$
|
31,476
|
|
|
$
|
36,980
|
|
|
$
|
32,422
|
|
|
$
|
28,488
|
|
|
$
|
24,931
|
|
|
$
|
107,038
|
|
|
|
(8) Segment Information
Our Chief Operating Decision Maker (the "CODM") evaluates segment operating performance using segment operating income. Segment operating income is defined as GAAP operating income excluding intangible amortization and amortization of fair value step-ups of inventory and fixed assets from acquisitions completed subsequent to December 31, 2011, the impact of restructuring related inventory write-offs, impairment charges and special charges or gains. The Company also refers to this measure as adjusted operating income. The Company uses this measure because it helps management understand and evaluate the segments’ core operating results and serves as the basis for determining incentive compensation achievement.
During the quarter ended March 29, 2020, the Company divested its I&S business, which was previously part of the Energy segment. See Note 5, Special and Restructuring Charges (Recoveries), net for additional information on this divestiture. In light of this divestiture, effective March 29, 2020, the Company realigned its segments by eliminating the Energy segment and moving the remaining businesses into the Industrial segment. Following the realignment the new reporting segments are Industrial and Aerospace & Defense, which is the level at which the CODM regularly reviews operating results.
The following table presents certain reportable segment information (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
Net revenues
|
|
|
|
|
|
|
|
Aerospace & Defense
|
$
|
60,001
|
|
|
$
|
65,493
|
|
|
|
|
|
Industrial
|
120,654
|
|
|
126,720
|
|
|
|
|
|
Consolidated net revenues
|
$
|
180,655
|
|
|
$
|
192,213
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Results from continuing operations before income taxes
|
|
|
|
|
|
|
|
Aerospace & Defense - Segment Operating Income
|
$
|
10,706
|
|
|
$
|
12,494
|
|
|
|
|
|
Industrial - Segment Operating Income
|
9,735
|
|
|
5,169
|
|
|
|
|
|
Corporate expenses
|
(8,002)
|
|
|
(6,588)
|
|
|
|
|
|
Subtotal
|
12,439
|
|
|
11,075
|
|
|
|
|
|
Restructuring charges, net
|
2,060
|
|
|
2,883
|
|
|
|
|
|
Special charges (recoveries), net
|
(2,869)
|
|
|
(45,175)
|
|
|
|
|
|
Special and restructuring charges (recoveries), net
|
(809)
|
|
|
(42,292)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring related inventory charges
|
—
|
|
|
(602)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition amortization
|
10,487
|
|
|
10,218
|
|
|
|
|
|
Acquisition depreciation
|
2,375
|
|
|
974
|
|
|
|
|
|
Impairment charges
|
—
|
|
|
116,182
|
|
|
|
|
|
Restructuring, impairment and other costs, net
|
12,862
|
|
|
126,772
|
|
|
|
|
|
Consolidated Operating Income (loss)
|
386
|
|
|
(73,405)
|
|
|
|
|
|
Interest expense, net
|
8,369
|
|
|
9,011
|
|
|
|
|
|
Other expense (income), net
|
(1,503)
|
|
|
(2,680)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations before income taxes
|
$
|
(6,480)
|
|
|
$
|
(79,736)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
Capital expenditures
|
|
|
|
|
|
|
|
Aerospace & Defense
|
$
|
1,286
|
|
|
$
|
640
|
|
|
|
|
|
Industrial
|
2,023
|
|
|
2,225
|
|
|
|
|
|
Corporate
|
153
|
|
|
198
|
|
|
|
|
|
Consolidated capital expenditures
|
$
|
3,462
|
|
|
$
|
3,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
Aerospace & Defense
|
$
|
2,824
|
|
|
$
|
3,093
|
|
|
|
|
|
Industrial
|
14,203
|
|
|
12,419
|
|
|
|
|
|
Corporate
|
178
|
|
|
125
|
|
|
|
|
|
Consolidated depreciation and amortization
|
$
|
17,205
|
|
|
$
|
15,637
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Identifiable assets
|
April 4, 2021
|
|
December 31, 2020
|
|
|
|
|
Aerospace & Defense
|
$
|
450,280
|
|
|
$
|
450,597
|
|
|
|
|
|
Industrial
|
1,359,942
|
|
|
1,378,710
|
|
|
|
|
|
Corporate
|
(687,020)
|
|
|
(698,779)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated identifiable assets
|
$
|
1,123,202
|
|
|
$
|
1,130,528
|
|
|
|
|
|
The total assets for each reportable segment have been reported as the Identifiable Assets for that segment, including inter-segment intercompany receivables, payables and investments in other CIRCOR subsidiaries. Identifiable assets reported in Corporate include both corporate assets, such as cash, deferred taxes, prepaid and other assets, fixed assets, as well as the
elimination of all inter-segment intercompany assets. The elimination of intercompany assets results in negative amounts reported in Corporate for Identifiable Assets.
(9) Financing Arrangements
Fair Value
The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:
•Level One: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.
•Level Two: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
•Level Three: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
The aggregate net fair value of the Company's interest rate swap, cross-currency swap, and foreign currency forward contract as of April 4, 2021 and December 31, 2020 are summarized in the table below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 2 - Significant Other Observable Inputs
|
|
|
|
|
|
April 4, 2021
|
|
December 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative assets
|
|
|
$
|
2,370
|
|
|
$
|
2,359
|
|
|
|
Derivative liabilities
|
|
|
$
|
(12,467)
|
|
|
$
|
(17,139)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The carrying amounts of cash and cash equivalents, restricted cash, trade receivables and trade payables approximate fair value because of the short term maturity of these financial instruments. Cash equivalents are carried at cost which approximates fair value at the balance sheet date and is a Level 1 financial instrument. As of April 4, 2021, the estimated fair value of our gross debt (before netting debt issuance costs) was $533.3 million, compared to carrying cost of $536.9 million. At December 31, 2020 the estimated fair value of our gross debt (before netting debt issuance costs) was $517.3 million, compared to carrying cost of $519.9 million. The Company's outstanding debt balances are characterized as Level 2 financial instruments.
Financial Instruments
As of April 4, 2021 and December 31, 2020, the Company had restricted cash balances of $1.3 million and $1.2 million, respectively. These balances are recorded within prepaid expenses and other current assets on the condensed consolidated balance sheets, and are included within cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows.
The Company has a receivable purchasing agreement with a bank whereby the Company can sell selected accounts receivable and obtain between 90% and 100% of the purchase price upfront, net of applicable discount fee, and the residual amount as the receivables are collected. During the three months ended April 4, 2021, the Company sold a total of $8.4 million of receivables under the program, receiving $8.2 million in upfront cash. During the three months ended March 29, 2020, the Company sold a total of $14.5 million of receivables and received $13.6 million in cash upfront. At April 4, 2021, a beneficial interest balance of $0.2 million was recorded in prepaid expenses and other current assets on the condensed consolidated balance sheet.
The Company has a cross-currency swap agreement to hedge its net investment in non-U.S. subsidiaries against future volatility in exchange rates between the U.S. dollar and the Euro. The cross-currency swap agreement is pursuant to an International Swaps and Derivatives Association ("ISDA") Master Agreement with Deutsche Bank AG. Should the counterparty cease to be part of the Company's secured lender group, the cross-currency agreement could be terminated early if acceptable substitute collateral arrangements (such as cash) are not put in place. The three-year cross-currency swap has a fixed notional value of
$100.0 million at an annual rate of 2.4065% and a maturity date of July 12, 2022. At inception, the cross-currency swap was designated as a net investment hedge. This hedging agreement mitigates foreign currency exchange rate exposure on the Company's net investment in Euro denominated subsidiaries and is not for speculative trading purposes. The net investment hedge was deemed effective as of quarter-end. As of April 4, 2021 and December 31, 2020, the cross-currency swap had a fair value liability of $2.9 million and $6.2 million, respectively.
The Company has an interest rate swap pursuant to an ISDA Master Agreement with Citizens Bank, National Association. The four-year interest rate swap has a fixed notional value of $400.0 million with a 1% LIBOR floor (in line with the Company's credit agreement) and a maturity date of April 12, 2022. The fixed rate of interest paid by the Company is comprised of our current credit spread of 325 basis points plus 2.6475% for a total interest rate of 5.8975%. The ISDA Master Agreement, together with its related schedules, contains customary representations, warranties, and covenants. The Company has designated the interest rate swap as a qualifying hedging instrument and is treating it as a cash flow hedge for accounting purposes pursuant to ASC 815, Derivatives and Hedging. As of April 4, 2021 and December 31, 2020, the interest rate swap had a fair value liability of $7.1 million and $8.6 million, respectively.
As of April 4, 2021, the Company had one EUR/SEK foreign currency forward contract with a notional value of EUR 10 million. There were no open forward contracts as of December 31, 2020. The fair value liability of the derivative forward contract was approximately $0.1 million and is included in accrued expenses and other current liabilities on our condensed consolidated balance sheet as of April 4, 2021. Our forward hedge contract falls within Level 2 of the fair value hierarchy, in accordance with ASC Topic 820. For the three months ended April 4, 2021, the realized and unrealized loss associated with this contract was $0.3 million, respectively. The intent of the foreign currency forward contract is to mitigate the risk of foreign exchange gains and losses on Euro-denominated balances at one of our non-Euro denominated functional currency entities. The forward contracts does not qualify for hedge accounting treatment. Any gains and losses are recognized as a component of other expense in our condensed consolidated statements of operations.
The aggregate net fair value of the interest rate swap, cross-currency swap, and foreign currency forward contract was a net liability position of $10.1 million and $14.8 million at April 4, 2021 and December 31, 2020, respectively. These balances are recorded in other non-current liabilities of $5.8 million, accrued expenses and other current liabilities of $6.7 million, and prepaid expenses and other current assets of $2.4 million on our condensed consolidated balance sheet as of April 4, 2021. As of December 31, 2020, these balances are recorded in other non-current liabilities of $10.6 million, accrued expenses and other current liabilities of $6.5 million, and prepaid expenses and other current assets of $2.4 million on our consolidated balance sheet.
The amount of gains (loss) recognized in other comprehensive (loss) income ("OCI") and reclassified from accumulated other comprehensive (loss) income ("AOCI") to earnings are summarized below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
Amount of (loss) recognized in OCI
|
|
|
|
|
$
|
(134)
|
|
|
$
|
(4,105)
|
|
|
|
|
|
|
|
|
|
|
|
Amount of (loss) reclassified from AOCI to earnings (interest expense, net)
|
|
|
|
|
$
|
(1,720)
|
|
|
$
|
(1,093)
|
|
|
Amounts expected to be reclassified from AOCI into interest expense in the next 12 months is a loss of $6.5 million. Interest expense (including the effects of the cash flow hedges) related to the portion of the Company's term loan subject to the aforementioned interest-rate swap agreement was $6.2 million for the three months ended April 4, 2021.
Debt
As of April 4, 2021, total debt was $525.6 million compared to $507.9 million as of December 31, 2020. Total debt is net of unamortized term loan debt issuance costs of $11.3 million and $12.0 million at April 4, 2021 and December 31, 2020, respectively. The Company made interest payments of $7.6 million and $8.8 million during the three months ended April 4, 2021, and March 29, 2020, respectively.
During the three months ended March 29, 2020, the Company paid down $161.8 million on its term loan from proceeds received through the sale of the I&S business. On March 20, 2020, the Company drew down $80 million on its line of credit due to concerns about possible disruptions to global capital markets stemming from COVID-19. The Company has since paid down its revolving credit facility balance by $35.1 million for a current balance of $44.9 million as of April 4, 2021.
During the first quarter of 2020, the Company amended its term loan to lower the interest rate associated with the applicable margin calculation. The new terms lower the interest rate on the Company's term loan from LIBOR plus an applicable margin of 3.5% to LIBOR plus an applicable margin of 3.25%, based on its existing corporate family rating from Moody's. The applicable margin reduces to LIBOR plus an applicable margin of 3.0%, with a corporate family rating from Moody's of B1 or better.
As part of the debt repricing, the Company's outstanding loan balance was reallocated amongst the lender group. The Company evaluated the changes in outstanding loan balance for each individual lender to determine the amount of capitalized debt issuance costs that required adjustment. Through this exercise, the Company determined that certain creditors under the original term loan did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $3.5 million in the first quarter of during Q1 2020 which was recorded to Special and restructuring charges (recoveries), net, on the condensed consolidated statement of operations. For the remainder of the creditors, this transaction was accounted for as a modification. The Company accounted for the amendment pursuant to ASC 470, subtopic 50-40, and third-party costs of $0.2 million related to this transaction were expensed and $0.3 million of lender fees were recorded as a reduction to debt representing deferred issuance costs.
(10) Guarantees and Indemnification Obligations
As permitted under Delaware law, the Company has agreements whereby it indemnifies certain of its officers and directors for certain events or occurrences while the officer or director is, or was, serving at its request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. However, it has directors’ and officers’ liability insurance policies that insure it with respect to certain events covered under the policies and should enable it to recover a portion of any future amounts paid under the indemnification agreements. The Company has no liabilities recorded from those agreements as of April 4, 2021.
The Company records provisions for the estimated cost of product warranties, primarily from historical information, at the time product revenue is recognized. The Company also records provisions with respect to any significant individual warranty issues as they arise. While the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure, and supplier warranties on parts delivered to us. Should actual product failure rates, utilization levels, material usage, service delivery costs or supplier warranties on parts differ from our estimates, revisions to the estimated warranty liability would be required.
The following table sets forth information related to product warranty reserves for the three months ended April 4, 2021 and March 29, 2020 (in thousands):
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Balance beginning December 31, 2020
|
$
|
2,206
|
|
Provisions
|
548
|
|
Claims settled
|
(629)
|
|
|
|
Currency translation adjustment
|
(21)
|
|
Balance ending April 4, 2021
|
$
|
2,104
|
|
|
|
Balance beginning December 31, 2019
|
$
|
1,642
|
|
Provisions
|
368
|
|
Claims settled
|
(682)
|
|
|
|
Currency translation adjustment
|
(29)
|
|
Balance ending March 29, 2020
|
$
|
1,299
|
|
Warranty obligations are recorded within Accrued expenses and other current liabilities on the condensed consolidated balance sheets.
(11) Commitments and Contingencies
The Company is subject to various legal proceedings and claims pertaining to matters such as product liability or contract disputes. The Company is also subject to other proceedings and governmental inquiries, inspections, audits or investigations pertaining to issues such as tax matters, patents and trademarks, pricing, business practices, governmental regulations, employment and other matters. Although the results of litigation and claims cannot be predicted with certainty, we expect that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, individually or in the aggregate, on our financial condition, results of operations or liquidity. During the three months ended April 4, 2021, the Company recognized recoveries for a business interruption insurance claim in the amount of $0.7 million, which is classified in the selling, general and administrative expenses on the condensed consolidated statement of operations.
Asbestos-related product liability claims continue to be filed against two of our subsidiaries: Spence Engineering Company, Inc. (“Spence”), the stock of which the Company acquired in 1984; and CIRCOR Instrumentation Technologies, Inc. (f/k/a Hoke, Inc.) (“Hoke”), the stock of which it acquired in 1998. The Hoke subsidiary was divested in January 2020 through our sale of the I&S business. However, the Company has indemnified the buyer for asbestos-related claims that are made against Hoke. Due to the nature of the products supplied by these entities, the markets they serve and our historical experience in resolving these claims, the Company does not expect that these asbestos-related claims will have a material adverse effect on the financial condition, results of operations or liquidity of the Company.
Standby Letters of Credit
The Company executes standby letters of credit, which include bid bonds and performance bonds, in the normal course of business to ensure performance or payments to third parties. The aggregate notional value of these instruments at April 4, 2021 was $27.3 million of which $19.6 million was syndicated under our credit agreement. This compares with aggregate notional value of $39.3 million of which $30.4 million was syndicated under our credit agreement as of December 31, 2020. The Company believes that the likelihood of demand for a significant payment relating to the outstanding instruments is remote. These instruments generally have expiration dates ranging from less than 1 month to 5 years from April 4, 2021.
(12) Retirement Plans
The following table sets forth the components of total net periodic benefit cost (income) of the Company’s defined benefit pension plans and other post-retirement employee benefit plans (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 4, 2021
|
|
March 29, 2020
|
|
|
|
|
Pension Benefits - U.S. Plans
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest cost
|
$
|
773
|
|
|
$
|
1,398
|
|
|
|
|
|
Expected return on plan assets
|
(2,629)
|
|
|
(2,747)
|
|
|
|
|
|
Amortization
|
51
|
|
|
43
|
|
|
|
|
|
Net periodic benefit income
|
$
|
(1,805)
|
|
|
$
|
(1,306)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension Benefits - Non-U.S. Plans
|
|
|
|
|
|
|
|
Service cost
|
$
|
823
|
|
|
$
|
692
|
|
|
|
|
|
Interest cost
|
247
|
|
|
339
|
|
|
|
|
|
Expected return on plan assets
|
(156)
|
|
|
(194)
|
|
|
|
|
|
Amortization
|
179
|
|
|
31
|
|
|
|
|
|
Net periodic benefit cost
|
$
|
1,093
|
|
|
$
|
868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Post-Retirement Benefits
|
|
|
|
|
|
|
|
Service cost
|
$
|
1
|
|
|
$
|
—
|
|
|
|
|
|
Interest cost
|
42
|
|
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit cost
|
$
|
43
|
|
|
$
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
The periodic benefit service costs are included in both costs of revenues, as well as selling, general, and administrative costs, while the remaining net periodic benefit costs are included in other expense (income), net in our condensed consolidated statements of operations for the quarters ended April 4, 2021 and March 29, 2020.
The Company did not make any employer contributions to the Company's U.S. or non-U.S. based defined benefit pension plans during the three months ended April 4, 2021. This is consistent with the three months ended March 29, 2020, in which the Company also did not make any contributions to the defined benefit pension plans.
(13) Income Taxes
The provision for (benefit from) income taxes to loss from continuing operations is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
April 4, 2021
|
|
March 29, 2020
|
Loss from Continuing Operations Before Income Taxes
|
|
$
|
(6,480)
|
|
|
$
|
(79,736)
|
|
Effective tax rate
|
|
(6.2)
|
%
|
|
(10.5)
|
%
|
Provision for (benefit from) income taxes
|
|
$
|
400
|
|
|
$
|
8,374
|
|
The Company is required to compute income tax expense in each jurisdiction in which it operates. This process requires the Company to project its current tax liability and estimate its deferred tax assets and liabilities, including net operating loss (“NOL”) and tax credit carryforwards. In assessing the ability to realize the net deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized.
The effective tax rate for the three months ended April 4, 2021, differed from the U.S. federal statutory rate of 21% primarily due to adjustments to the domestic and foreign valuation allowances and adjustments related to uncertain tax positions. The effective tax rate for the three months ended March 29, 2020, differed from the U.S. federal statutory rate primarily due to non-deductible expenses, goodwill impairment and dispositions. In 2020 the Company recorded a full valuation allowance in the US and Germany. The Company intends to continue maintaining valuation allowances on these deferred tax assets until there is sufficient evidence to support the release of all or some portion of these allowances.
As of April 4, 2021 and December 31, 2020, the Company had $1.5 million and $1.1 million, respectively, of unrecognized tax benefits, all of which would affect our effective tax rate if recognized in any future period.
(14) Share-Based Compensation
As of April 4, 2021, the Company had 640,010 stock options and 742,390 Restricted Stock Unit Awards ("RSU Awards") and Restricted Stock Unit Management Stock Plan Awards ("RSU MSPs") outstanding. On May 9, 2019, our shareholders approved the 2019 Stock Option and Incentive Plan (the "2019 Plan") at the Company's annual meeting which was adopted, subject to shareholder approval, by the Company's board of directors on February 20, 2019. The 2019 Plan authorizes issuance of up to 1,000,000 shares of common stock (subject to adjustment for stock splits and similar events). Under the 2019 Plan, there were 205,045 shares available for grant as of April 4, 2021.
During the three months ended April 4, 2021 and March 29, 2020, there were no stock options granted.
For additional information regarding the historical issuance of stock options, refer to Note 13 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
During the three months ended April 4, 2021 and March 29, 2020, the Company granted 233,618 and 552,010 RSU Awards with approximate fair values of $40.85 and $12.70 per RSU Award, respectively. During the three months ended April 4, 2021 and March 29, 2020, the Company granted performance-based RSU Awards as part of the overall mix of RSU Awards. Of the 233,618 RSU Awards granted during the three months ended April 4, 2021, 70,933 are performance-based RSU Awards. This compares to 109,278 performance-based RSU Awards granted during the three months ended March 29, 2020. In 2021, these performance-based RSU Awards granted with a market condition are based on the Company's total shareholder return relative
to a subset of the S&P 600 SmallCap Industrial Companies over a three year performance period. The target payout range for the 2021 award is 0% to 200% with a cap not to exceed 600% of the target value on the grant date. The 2021 performance-based RSUs are valued using a Monte Carlo Simulation model to account for the market condition on grant date. In 2020, the performance-based RSUs include metrics for achieving Adjusted Operating Margin and Adjusted Measurement Cash Flow with target payouts ranging from 0% to 200%. Of the different performance-based RSU tranches without a market condition, the Company anticipates approximately 6% overall achievement and probability to vest.
There were 31,248 RSU MSPs granted during the three months ended April 4, 2021. RSU MSPs granted during the three months ended April 4, 2021 had a per unit discount of $13.14 per share representing fair value. No RSU MSPs were granted during the three months ended March 29, 2020.
Compensation expense related to the Company's share-based plans for the three months ended April 4, 2021 and March 29, 2020 was $1.4 million and $0.7 million, respectively. The increase in 2021 expense is primarily due to higher performance-based RSU expense. Compensation expense for three months ended April 4, 2021 was recorded in selling, general and administrative expenses. Compensation expense for the three months ended March 29, 2020 was recorded as follows: $0.6 million in selling, general and administrative expenses and $0.1 million in special charges related to the sale of the Company's I&S business. The special charges relate to the accelerated vesting of awards as a result of the sale transactions. As of April 4, 2021, there were $13.6 million of total unrecognized compensation costs related to the Company's outstanding share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of 2.5 years.
The weighted average contractual term for stock options outstanding and options exercisable as of April 4, 2021 was 2.9 years and 2.8 years, respectively. The aggregate intrinsic value of stock options exercised during the three months ended April 4, 2021 was insignificant. The aggregate intrinsic value of stock options outstanding and exercisable as of April 4, 2021 was $0.2 million and $0.2 million, respectively.
The aggregate intrinsic value of RSU Awards settled during the three months ended April 4, 2021 was $8.3 million and the aggregate intrinsic value of RSU Awards outstanding as of April 4, 2021 was $23.4 million.
The aggregate intrinsic values of RSU MSPs settled during the three months ended April 4, 2021 was $0.2 million and the aggregate intrinsic value of RSU MSPs outstanding as of April 4, 2021 was $0.9 million.
The Company also grants cash settled stock unit awards to some of its international employee participants. Cash settled stock unit award related compensation costs for the three months ended April 4, 2021 and March 29, 2020 were immaterial.
(15) Accumulated Other Comprehensive Loss
The following table summarizes the changes in accumulated other comprehensive loss, net of tax, which is reported as a component of shareholders' equity, for the three months ended April 4, 2021 and March 29, 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign Currency Translation Adjustments
|
|
Pension, net
|
|
Derivative
|
|
Total
|
Balance as of December 31, 2020
|
$
|
(46,899)
|
|
|
$
|
(33,359)
|
|
|
$
|
(5,710)
|
|
|
$
|
(85,968)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) income
|
(3,594)
|
|
|
60
|
|
|
1,586
|
|
|
(1,948)
|
|
Balance as of April 4, 2021
|
$
|
(50,493)
|
|
|
$
|
(33,299)
|
|
|
$
|
(4,124)
|
|
|
$
|
(87,916)
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2019
|
$
|
(53,848)
|
|
|
$
|
(19,513)
|
|
|
$
|
(6,906)
|
|
|
$
|
(80,267)
|
|
Other comprehensive (loss) income
|
(20,325)
|
|
|
39
|
|
|
(2,320)
|
|
|
(22,606)
|
|
Balance as of March 29, 2020
|
$
|
(74,173)
|
|
|
$
|
(19,474)
|
|
|
$
|
(9,226)
|
|
|
$
|
(102,873)
|
|
(16) Income (Loss) Per Common Share ("EPS")
For the three months ended April 4, 2021, and March 29, 2020, outstanding stock options, RSU Awards and RSU MSPs were not included in the calculation of dilutive EPS because to do so would be anti-dilutive. Certain stock options to purchase
common shares and restricted stock units ("RSUs") were anti-dilutive. For the three months ended April 4, 2021, there were 870,829 anti-dilutive stock options, RSUs, and RSU MSPs with exercise prices ranging from $33.63 to $60.99. For the three months ended March 29, 2020, there were 417,932 anti-dilutive stock options, RSUs, and RSU MSPs with exercise prices ranging from $33.63 to $71.56.